Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Labetuzumab govitecan - Immunomedics

Next Previous
Drug Profile

Labetuzumab govitecan - Immunomedics

Alternative Names: Anti-carcinoembryonic antigen monoclonal antibody; Anti-CEA monoclonal antibody; anti-CEACAM5-SN-38; GS-0130; hMN-14-SN38; hMN-14-SN38 antibody-drug conjugate; IMMU-0130; IMMU-130; Labetuzumab-SN38 conjugate; SN38-labetuzumab conjugate

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Pyrrolidines; Quinolines; Triazoles
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer

Most Recent Events

  • 03 Dec 2020 Immunomedics withdraws enrolment in a phase II trial prior to enrollment for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (NCT01915472)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 30 Jul 2018 Immunomedics signs a research collaboration agreement with Fred Hutchinson Cancer Research Center for evaluation of labetuzumab govitecan in the treatment of Prostate cancer (Combination therapy)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top